Host |
Rat |
Klon |
M1/70.15 |
Format |
Purified |
Methode |
F, P, IP, FL |
Isotyp |
Rat IgG2b |
Verdünnung |
T cell enriched splenocytes from B10 mice |
CD11b (alpha M integrin)
|
Zytomed Systems GmbH |
M1/70.15 |
250 µg |
Purified |
RUO |
603-0461 |
-
|
Host |
Rat |
Klon |
M1/70.15 |
Format |
Purified |
Methode |
F, P, IP, FL |
Isotyp |
Rat IgG2b |
Verdünnung |
T cell enriched splenocytes from B10 mice |
CD11b (alpha M integrin)
|
Zytomed Systems GmbH |
M1/70.15 |
100 µg |
Purified |
RUO |
603-0462 |
-
|
Host |
Mouse |
Klon |
5D11 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Skin |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cell membrane |
CD11c
|
Biocare Medical |
5D11 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3122A |
-
|
Host |
Mouse |
Klon |
5D11 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Skin |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cell membrane |
CD11c
|
Biocare Medical |
5D11 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3122B |
-
|
Host |
Mouse |
Klon |
5D11 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Skin |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cell membrane |
CD11c
|
Biocare Medical |
5D11 |
6 ml |
Ready-to-use |
CE/IVD |
API3122AA |
-
|
Host |
Monospecific Mouse |
Klon |
ZM103 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human ITGAX protein fragment (aa 637-827) |
Lokalisation |
Cell membrane |
CD11c
|
Zeta Corporation |
ZM103 |
1 ml |
Concentrate |
CE/IVD |
Z2414ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM103 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human ITGAX protein fragment (aa 637-827) |
Lokalisation |
Cell membrane |
CD11c
|
Zeta Corporation |
ZM103 |
7 ml |
Ready-to-use |
CE/IVD |
Z2414MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM103 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human ITGAX protein fragment (aa 637-827) |
Lokalisation |
Cell membrane |
CD11c
|
Zeta Corporation |
ZM103 |
0.5 ml |
Concentrate |
CE/IVD |
Z2414MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM103 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human ITGAX protein fragment (aa 637-827) |
Lokalisation |
Cell membrane |
CD11c
|
Zeta Corporation |
ZM103 |
0.1 ml |
Concentrate |
CE/IVD |
Z2414MT |
-
|
Host |
Mouse |
Klon |
ZM287 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /k |
Verdünnung |
Recombinant fragment (around a50-250) of human ANPEP protein |
Lokalisation |
Cytoplasm |
CD13
|
Zeta Corporation |
ZM287 |
1 ml |
Concentrate |
CE/IVD |
Z2524ML |
-
|
Host |
Mouse |
Klon |
ZM287 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bone marrow |
Verdünnung |
- |
Isotyp |
IgG1 /k |
Verdünnung |
Recombinant fragment (around a50-250) of human ANPEP protein |
Lokalisation |
Cytoplasm |
CD13
|
Zeta Corporation |
ZM287 |
7 ml |
Ready-to-use |
CE/IVD |
Z2524MP |
-
|
Host |
Mouse |
Klon |
ZM287 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /k |
Verdünnung |
Recombinant fragment (around a50-250) of human ANPEP protein |
Lokalisation |
Cytoplasm |
CD13
|
Zeta Corporation |
ZM287 |
0.5 ml |
Concentrate |
CE/IVD |
Z2524MS |
-
|
Host |
Mouse |
Klon |
ZM287 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /k |
Verdünnung |
Recombinant fragment (around a50-250) of human ANPEP protein |
Lokalisation |
Cytoplasm |
CD13
|
Zeta Corporation |
ZM287 |
0.1 ml |
Concentrate |
CE/IVD |
Z2524MT |
-
|
Host |
Mouse |
Klon |
MMA |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM kappa |
Lokalisation |
Cell Membrane |
CD15
|
Diagnostic Biosystems |
MMA |
1 ml |
Concentrate |
CE/IVD |
MOB365 |
-
|
Host |
Mouse |
Klon |
MMA |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM kappa |
Lokalisation |
Cell Membrane |
CD15
|
Diagnostic Biosystems |
MMA |
0.1 ml |
Concentrate |
CE/IVD |
MOB365-01 |
-
|
Host |
Mouse |
Klon |
MMA |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM kappa |
Lokalisation |
Cell Membrane |
CD15
|
Diagnostic Biosystems |
MMA |
0.5 ml |
Concentrate |
CE/IVD |
MOB365-05 |
-
|
Host |
Mouse |
Klon |
MMA |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgM kappa |
Lokalisation |
Cell Membrane |
CD15
|
Diagnostic Biosystems |
MMA |
6 ml |
Ready-to-use |
CE/IVD |
PDM127 |
-
|
Host |
Mouse |
Klon |
MMA |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgM |
Verdünnung |
Glycoprotein fraction of human lymphocytes |
Lokalisation |
Cell membrane and granular periNucleus |
CD15
|
Zeta Corporation |
MMA |
1.0 ml |
Concentrate |
CE/IVD |
Z2028ML |
-
|
Host |
Mouse |
Klon |
MMA |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma. |
Verdünnung |
- |
Isotyp |
IgM |
Verdünnung |
Glycoprotein fraction of human lymphocytes |
Lokalisation |
Cell membrane and granular periNucleus |
CD15
|
Zeta Corporation |
MMA |
7 ml |
Ready-to-use |
CE/IVD |
Z2028MP |
-
|
Host |
Mouse |
Klon |
MMA |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgM |
Verdünnung |
Glycoprotein fraction of human lymphocytes |
Lokalisation |
Cell membrane and granular periNucleus |
CD15
|
Zeta Corporation |
MMA |
0.5 ml |
Concentrate |
CE/IVD |
Z2028MS |
-
|
Host |
Mouse |
Klon |
MMA |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgM |
Verdünnung |
Glycoprotein fraction of human lymphocytes |
Lokalisation |
Cell membrane and granular periNucleus |
CD15
|
Zeta Corporation |
MMA |
0.1 ml |
Concentrate |
CE/IVD |
Z2028MT |
-
|
Host |
Rabbit |
Klon |
SP189 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung, Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human CD16a protein |
Lokalisation |
Cell Membrane |
CD16a
|
Zytomed Systems GmbH |
SP189 |
0.5 ml |
Concentrate |
RUO |
506-4892 |
-
|
Host |
Rabbit |
Klon |
SP189 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung, Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human CD16a protein |
Lokalisation |
Cell Membrane |
CD16a
|
Zytomed Systems GmbH |
SP189 |
1 ml |
Concentrate |
RUO |
506-4894 |
-
|
Host |
Rat |
Klon |
YFC118.3 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Rat IgG2b |
Verdünnung |
Human neutrophils |
CD18 (Integrin beta2, LFA-1 beta2)
|
Zytomed Systems GmbH |
YFC118.3 |
100 µg |
Purified |
RUO |
603-0574 |
-
|
Host |
Rabbit |
Klon |
SP110 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of human CD19 |
Lokalisation |
Cell Membrane |
CD19
|
Zytomed Systems GmbH |
SP110 |
0.5 ml |
Concentrate |
RUO |
520-4102 |
-
|
Host |
Rabbit |
Klon |
SP110 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of human CD19 |
Lokalisation |
Cell Membrane |
CD19
|
Zytomed Systems GmbH |
SP110 |
1 ml |
Concentrate |
RUO |
520-4104 |
-
|
Host |
Rat |
Klon |
6D5 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Rat IgG2a |
Verdünnung |
Human K562 cell line transfected with murine CD19 |
CD19
|
Zytomed Systems GmbH |
6D5 |
250 µg |
Purified |
RUO |
603-0597 |
-
|
Host |
Rat |
Klon |
6D5 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Rat IgG2a |
Verdünnung |
Human K562 cell line transfected with murine CD19 |
CD19
|
Zytomed Systems GmbH |
6D5 |
100 µg |
Purified |
RUO |
603-0598 |
-
|
Host |
Rabbit |
Klon |
RM332 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane |
CD19
|
Biocare Medical |
RM332 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3270G |
-
|
Host |
Mouse |
Klon |
LE-CD19 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptid corresponding to the C-terminus of human CD19 |
Lokalisation |
Cell membrane, Cytoplasm |
CD19
|
Zytomed Systems GmbH |
LE-CD19 |
0.5 ml |
Concentrate |
RUO |
MSK043-05 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM179 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide from the c-terminus of human CD19 protein |
Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZM179 |
1 ml |
Concentrate |
CE/IVD |
Z2481ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM179 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or tonsil |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide from the c-terminus of human CD19 protein |
Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZM179 |
7 ml |
Ready-to-use |
CE/IVD |
Z2481MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM179 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide from the c-terminus of human CD19 protein |
Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZM179 |
0.5 ml |
Concentrate |
CE/IVD |
Z2481MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM179 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
A synthetic peptide from the c-terminus of human CD19 protein |
Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZM179 |
0.1 ml |
Concentrate |
CE/IVD |
Z2481MT |
-
|
Host |
Rabbit |
Klon |
ZR212 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph node or tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human CD19 protein (around aa96-281) |
Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZR212 |
1.0 ml |
Concentrate |
CE/IVD |
Z2547RL |
-
|
Host |
Rabbit |
Klon |
ZR212 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph node or tonsil. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human CD19 protein (around aa96-281) |
Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZR212 |
7 ml |
Ready-to-use |
CE/IVD |
Z2547RP |
-
|
Host |
Rabbit |
Klon |
ZR212 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph node or tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human CD19 protein (around aa96-281) |
Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZR212 |
0.5 ml |
Concentrate |
CE/IVD |
Z2547RS |
-
|
Host |
Rabbit |
Klon |
ZR212 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph node or tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human CD19 protein (around aa96-281) |
Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZR212 |
0.1 ml |
Concentrate |
CE/IVD |
Z2547RT |
-
|
Host |
Rabbit |
Klon |
SP32 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
- |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of human CD20. |
Lokalisation |
Cytoplasm, Cell Membrane |
CD20
|
Zytomed Systems GmbH |
SP32 |
1 ml |
Concentrate |
RUO |
RBK030 |
-
|
Host |
Rabbit |
Klon |
SP32 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
- |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of human CD20. |
Lokalisation |
Cytoplasm, Cell Membrane |
CD20
|
Zytomed Systems GmbH |
SP32 |
0.5 ml |
Concentrate |
RUO |
RBK030-05 |
-
|
Host |
Mouse |
Klon |
L26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
1:100 - 1:300 |
Isotyp |
IgG2a /κ |
Verdünnung |
Human tonsil B cells |
Lokalisation |
Cell membrane/Cytoplasm |
CD20
|
Zeta Corporation |
L26 |
1ml |
Concentrate |
CE/IVD |
Z2059ML |
-
|
Host |
Mouse |
Klon |
L26 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Human tonsil B cells |
Lokalisation |
Cell membrane/Cytoplasm |
CD20
|
Zeta Corporation |
L26 |
7 ml |
Ready-to-use |
CE/IVD |
Z2059MP |
-
|
Host |
Mouse |
Klon |
L26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
1:100 - 1:300 |
Isotyp |
IgG2a /κ |
Verdünnung |
Human tonsil B cells |
Lokalisation |
Cell membrane/Cytoplasm |
CD20
|
Zeta Corporation |
L26 |
0.5 ml |
Concentrate |
CE/IVD |
Z2059MS |
-
|
Host |
Mouse |
Klon |
L26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node. |
Verdünnung |
1:100 - 1:300 |
Isotyp |
IgG2a /κ |
Verdünnung |
Human tonsil B cells |
Lokalisation |
Cell membrane/Cytoplasm |
CD20
|
Zeta Corporation |
L26 |
0.1 ml |
Concentrate |
CE/IVD |
Z2059MT |
-
|
Host |
Rabbit |
Klon |
ZR243 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node |
Verdünnung |
1:100 - 1:300 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 197-297) of human MS4A1 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface |
CD20
|
Zeta Corporation |
ZR243 |
1 ml |
Concentrate |
RUO |
Z2717RL-R |
-
|
Host |
Rabbit |
Klon |
ZR243 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 197-297) of human MS4A1 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface |
CD20
|
Zeta Corporation |
ZR243 |
7 ml |
Concentrate |
RUO |
Z2717RP-R |
-
|
Host |
Rabbit |
Klon |
ZR243 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node |
Verdünnung |
1:100 - 1:300 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 197-297) of human MS4A1 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface |
CD20
|
Zeta Corporation |
ZR243 |
0.5 ml |
Concentrate |
RUO |
Z2717RS-R |
-
|
Host |
Rabbit |
Klon |
ZR243 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil, lymph node |
Verdünnung |
1:100 - 1:300 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 197-297) of human MS4A1 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface |
CD20
|
Zeta Corporation |
ZR243 |
0.1 ml |
Concentrate |
RUO |
Z2717RT-R |
-
|
Host |
Mouse |
Klon |
1F8 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD21
|
Diagnostic Biosystems |
1F8 |
1 ml |
Concentrate |
CE/IVD |
MOB028 |
-
|
Host |
Mouse |
Klon |
1F8 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD21
|
Diagnostic Biosystems |
1F8 |
0.1 ml |
Concentrate |
CE/IVD |
MOB028-01 |
-
|